F-14413
| Clinical data | |
|---|---|
| Other names | F14413; 5-Fluoro-methoxyidazoxan |
| Routes of administration | Unspecified[1] |
| Drug class | α2-Adrenergic receptor antagonist or inverse agonist |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C12H13FN2O3 |
| Molar mass | 252.245 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
F-14413, also known as 5-fluoro-methoxyidazoxan, is an α2-adrenergic receptor antagonist or inverse agonist which was under development for the treatment of Alzheimer's disease and Parkinson's disease in France but was never marketed.[1][2][3][4] It is a derivative of idazoxan.[3][4] The drug's route of administration was unspecified.[1] It is said to be potent and highly selective as an α2-adrenergic receptor modulator.[5][4] F-14413 was under development by Pierre Fabre.[1][2][5] It reached the preclinical research stage of development prior to its discontinuation.[1][2] F-14413 was first described in the scientific literature by 2001,[5] while its latest developmental update was in 2003.[1]
See also
References
- ^ a b c d e f "F 14413". AdisInsight. 16 November 2009. Retrieved 30 May 2026.
- ^ a b c "Delving into the Latest Updates on F-14413 with Synapse". Synapse. 25 April 2026. Retrieved 30 May 2026.
- ^ a b Veyrac A, Didier A, Colpaert F, Jourdan F, Marien M (August 2005). "Activation of noradrenergic transmission by alpha2-adrenoceptor antagonists counteracts deafferentation-induced neuronal death and cell proliferation in the adult mouse olfactory bulb". Experimental Neurology. 194 (2): 444–456. doi:10.1016/j.expneurol.2005.03.004. PMID 16022870.
- ^ a b c Kalinin S, Polak PE, Madrigal JL, Gavrilyuk V, Sharp A, Chauhan N, et al. (2006). "Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist". Antioxidants & Redox Signaling. 8 (5–6): 873–883. doi:10.1089/ars.2006.8.873. PMID 16771677.
- ^ a b c Belin R, Tillard M, Maurel JL, Ribet JP (April 2001). "Absolute configuration of (+)-(S)-2-(5-fluoro-2-methoxy-1,4-benzodioxan-2-yl)imidazolinium bromide". Acta Crystallographica. Section C, Crystal Structure Communications. 57 (Pt 4): 483–484. Bibcode:2001AcCrC..57..483B. doi:10.1107/s0108270101000981. PMID 11313601.